FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171404744> ?p ?o ?g. }

• W2171404744 endingPage "398" @default.
• W2171404744 startingPage "387" @default.
• W2171404744 abstract "Reports of the phase III clinical trials on four combined progestogen-estrogen once-a-month injectable contraceptives, Deladroxate, Cyclofem, Mesigyna and Chinese Injectable No. 1, are reviewed focussing on efficacy and reasons for discontinuation. Deladroxate, currently used in many Latin American countries has proved to be highly effective and well accepted. However, this combination was withdrawn by the original manufacturer because the progestogen component of this drug induced a high number of breast cancers in dogs and very curious pituitary hyperplasia in rats. Cyclofem and Mesigyna were found to be highly effective and highly acceptable drugs. Side-effects were minimal and were of minor importance. The Chinese Injectable No. 1 had unacceptably high failure rates with a monthly injection schedule. After doubling the dose in the first month of use, the efficacy was satisfactory. It was found that all monthly injectable contraceptives provided better cycle control than the every 3 months depot-medroxyprogesterone acetate, although abnormal bleeding was still the main drug-related complaint and reason for discontinuation. Missed appointment is another reason for discontinuation which might reflect the problem of frequent injection schedule, thus indicating the need for proper selection of the users and good counselling.This literature review examines the efficacy and reasons for discontinuation of 4 combined progestogen-estrogen, once-a-month injectable contraceptives: Deladroxate, Cyclofem, Mesigyna, and Chinese injectable No. 1. Deladroxate is used mainly in Latin America, while the Chinese injectable No. 1 is largely limited to China. Among 18 studies, no pregnancies occurred in the 3017 women using Deladroxate (32,857 woman-months). It was well accepted, but the manufacturer withdrew it from the market after studies showed that the progestogen (dihydroxyprogesterone acetophenide) caused dogs to develop breast cancer and rats to develop an odd pituitary hyperplasia. Of the 4 once-a-month injectables, Cyclofem and Mesigyna provide the most promise. They are very effective at preventing pregnancy (0-0.23/100 women-years of use and 0.08-0.48/100 women-years of use, respectively). Acceptance of Cyclofem and Mesigyna was high. Side effects were limited and had minimal importance. An advantage of Cyclofem and Mesigyna is their much better cycle control than the once-every-3 months injectable Depo-Provera. The failure rate of the Chinese Injectable No. 1 on the once-a-month injection schedule was too high (10.35/100 women-years of use). When researchers doubled the dose in the 1st month of use, however, efficacy was satisfactory (0.8/100 women-years of use). The main drug-related complaint and reason for discontinuation of all once-a-month injectables was abnormal bleeding. Another key reason for discontinuation was missed appointment, suggesting that a frequent injection schedule poses a problem. Good planning and health workers properly selecting users and providing them good counseling may overcome this problem. Frequent visits would increase the staff work load." @default.
• W2171404744 created "2016-06-24" @default.
• W2171404744 creator A5062609087 @default.
• W2171404744 date "1994-04-01" @default.
• W2171404744 modified "2023-09-27" @default.
• W2171404744 title "Once-a-month injectable contraceptives: efficacy and reasons for discontinuation" @default.
• W2171404744 cites W1439644710 @default.
• W2171404744 cites W1523962364 @default.
• W2171404744 cites W1970034055 @default.
• W2171404744 cites W1976746909 @default.
• W2171404744 cites W1990549650 @default.
• W2171404744 cites W2025588518 @default.
• W2171404744 cites W2065922977 @default.
• W2171404744 cites W2075729723 @default.
• W2171404744 cites W2124931525 @default.
• W2171404744 cites W2138050543 @default.
• W2171404744 cites W2191279706 @default.
• W2171404744 cites W2278233009 @default.
• W2171404744 cites W2297217204 @default.
• W2171404744 cites W2299110633 @default.
• W2171404744 cites W2408259604 @default.
• W2171404744 cites W2465090397 @default.
• W2171404744 cites W4298376032 @default.
• W2171404744 doi "https://doi.org/10.1016/0010-7824(94)90034-5" @default.
• W2171404744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8013221" @default.
• W2171404744 hasPublicationYear "1994" @default.
• W2171404744 type Work @default.
• W2171404744 sameAs 2171404744 @default.
• W2171404744 citedByCount "24" @default.
• W2171404744 countsByYear W21714047442015 @default.
• W2171404744 countsByYear W21714047442020 @default.
• W2171404744 countsByYear W21714047442022 @default.
• W2171404744 crossrefType "journal-article" @default.
• W2171404744 hasAuthorship W2171404744A5062609087 @default.
• W2171404744 hasConcept C126322002 @default.
• W2171404744 hasConcept C131872663 @default.
• W2171404744 hasConcept C141071460 @default.
• W2171404744 hasConcept C160050368 @default.
• W2171404744 hasConcept C2776306185 @default.
• W2171404744 hasConcept C2777164284 @default.
• W2171404744 hasConcept C2778715236 @default.
• W2171404744 hasConcept C2779076696 @default.
• W2171404744 hasConcept C2780572241 @default.
• W2171404744 hasConcept C2908647359 @default.
• W2171404744 hasConcept C29456083 @default.
• W2171404744 hasConcept C2986817661 @default.
• W2171404744 hasConcept C71924100 @default.
• W2171404744 hasConcept C81603835 @default.
• W2171404744 hasConcept C98274493 @default.
• W2171404744 hasConcept C99454951 @default.
• W2171404744 hasConceptScore W2171404744C126322002 @default.
• W2171404744 hasConceptScore W2171404744C131872663 @default.
• W2171404744 hasConceptScore W2171404744C141071460 @default.
• W2171404744 hasConceptScore W2171404744C160050368 @default.
• W2171404744 hasConceptScore W2171404744C2776306185 @default.
• W2171404744 hasConceptScore W2171404744C2777164284 @default.
• W2171404744 hasConceptScore W2171404744C2778715236 @default.
• W2171404744 hasConceptScore W2171404744C2779076696 @default.
• W2171404744 hasConceptScore W2171404744C2780572241 @default.
• W2171404744 hasConceptScore W2171404744C2908647359 @default.
• W2171404744 hasConceptScore W2171404744C29456083 @default.
• W2171404744 hasConceptScore W2171404744C2986817661 @default.
• W2171404744 hasConceptScore W2171404744C71924100 @default.
• W2171404744 hasConceptScore W2171404744C81603835 @default.
• W2171404744 hasConceptScore W2171404744C98274493 @default.
• W2171404744 hasConceptScore W2171404744C99454951 @default.
• W2171404744 hasIssue "4" @default.
• W2171404744 hasLocation W21714047441 @default.
• W2171404744 hasLocation W21714047442 @default.
• W2171404744 hasOpenAccess W2171404744 @default.
• W2171404744 hasPrimaryLocation W21714047441 @default.
• W2171404744 hasRelatedWork W1504803325 @default.
• W2171404744 hasRelatedWork W2001363469 @default.
• W2171404744 hasRelatedWork W2020690897 @default.
• W2171404744 hasRelatedWork W2034341851 @default.
• W2171404744 hasRelatedWork W2061945081 @default.
• W2171404744 hasRelatedWork W2081232579 @default.
• W2171404744 hasRelatedWork W2946801443 @default.
• W2171404744 hasRelatedWork W2273978288 @default.
• W2171404744 hasRelatedWork W2287860787 @default.
• W2171404744 hasRelatedWork W2732087922 @default.
• W2171404744 hasVolume "49" @default.
• W2171404744 isParatext "false" @default.
• W2171404744 isRetracted "false" @default.
• W2171404744 magId "2171404744" @default.
• W2171404744 workType "article" @default.